Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

Merck is ending a Phase 3 trial of Winrevair early so all PAH patients in HYPERION can start active treatment with the drug ...

Close your eyes and take a deep breath. Feels normal, right? Imagine if that breath carried invisible toxins, invisible yet powerful enough to weaken our body from inside? For millions of young people ...

Among adults hospitalized with influenza, Tamiflu treatment on the day of hospital admission was associated with a reduced risk for disease progression.

During and after an exacerbation, mental recovery involves taking care of both your physical and mental health. Resting, ...

The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...

LANGHORNE, Pa. - Savara Inc. (NASDAQ:SVRA), a biopharmaceutical company specializing in rare respiratory diseases with a ...

Merck said the Phase 3 "Hyperion" study, which was evaluating Winrevair versus placebo in recently diagnosed adults with PAH at intermediate or high risk of disease progression, had lost clinical ...

Receiving a diagnosis for any disease/condition is not an easy experience. One organization hopes to make patients newly diagnosed with pulmonary fibrosis feel supported during this time via a new ...

The trial's safety results were reassuring, with no serious adverse events or significant changes in vital signs, physical exams, or safety laboratory values post-administration of TX45. Transient ...

Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...